KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation

César Serrano; Yuexiang Wang; Adrián Mariño-Enríquez; Jen Chieh Lee; Gloria Ravegnini; Jeffrey A. Morgan; Monica M. Bertagnolli; Carol Beadling; George D. Demetri; Christopher L. Corless; Michael C. Heinrich; Jonathan A. Fletcher

doi:10.1200/JCO.2013.48.7488

KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation

César Serrano
, Yuexiang Wang
, Adrián Mariño-Enríquez
, Jen Chieh Lee
, Gloria Ravegnini
, Jeffrey A. Morgan
, Monica M. Bertagnolli
, Carol Beadling
, George D. Demetri
, Christopher L. Corless
, Michael C. Heinrich
, Jonathan A. Fletcher

Knight Cancer Institute

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Original language	English (US)
Pages (from-to)	e93-e96
Journal	Journal of Clinical Oncology
Volume	33
Issue number	22
DOIs	https://doi.org/10.1200/JCO.2013.48.7488
State	Published - Aug 1 2015

Funding

Funders	Funder number
National Institute of Health-National Cancer Institute	P50CA127003

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2013.48.7488

Cite this

Serrano, C., Wang, Y., Mariño-Enríquez, A., Lee, J. C., Ravegnini, G., Morgan, J. A., Bertagnolli, M. M., Beadling, C., Demetri, G. D., Corless, C. L., Heinrich, M. C., & Fletcher, J. A. (2015). KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation. Journal of Clinical Oncology, 33(22), e93-e96. https://doi.org/10.1200/JCO.2013.48.7488

KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation. / Serrano, César; Wang, Yuexiang; Mariño-Enríquez, Adrián et al.
In: Journal of Clinical Oncology, Vol. 33, No. 22, 01.08.2015, p. e93-e96.

Research output: Contribution to journal › Article › peer-review

Serrano, C, Wang, Y, Mariño-Enríquez, A, Lee, JC, Ravegnini, G, Morgan, JA, Bertagnolli, MM, Beadling, C, Demetri, GD, Corless, CL , Heinrich, MC & Fletcher, JA 2015, 'KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation', Journal of Clinical Oncology, vol. 33, no. 22, pp. e93-e96. https://doi.org/10.1200/JCO.2013.48.7488

@article{5707304ed7404ff2b6854840f086929a,

title = "KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation",

author = "C{\'e}sar Serrano and Yuexiang Wang and Adri{\'a}n Mari{\~n}o-Enr{\'i}quez and Lee, \{Jen Chieh\} and Gloria Ravegnini and Morgan, \{Jeffrey A.\} and Bertagnolli, \{Monica M.\} and Carol Beadling and Demetri, \{George D.\} and Corless, \{Christopher L.\} and Heinrich, \{Michael C.\} and Fletcher, \{Jonathan A.\}",

year = "2015",

month = aug,

day = "1",

doi = "10.1200/JCO.2013.48.7488",

language = "English (US)",

volume = "33",

pages = "e93--e96",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "22",

}

TY - JOUR

T1 - KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors

T2 - Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation

AU - Serrano, César

AU - Wang, Yuexiang

AU - Mariño-Enríquez, Adrián

AU - Lee, Jen Chieh

AU - Ravegnini, Gloria

AU - Morgan, Jeffrey A.

AU - Bertagnolli, Monica M.

AU - Beadling, Carol

AU - Demetri, George D.

AU - Corless, Christopher L.

AU - Heinrich, Michael C.

AU - Fletcher, Jonathan A.

PY - 2015/8/1

Y1 - 2015/8/1

UR - https://www.scopus.com/pages/publications/84941283441

UR - https://www.scopus.com/pages/publications/84941283441#tab=citedBy

U2 - 10.1200/JCO.2013.48.7488

DO - 10.1200/JCO.2013.48.7488

M3 - Article

C2 - 24687822

AN - SCOPUS:84941283441

SN - 0732-183X

VL - 33

SP - e93-e96

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 22

ER -

KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this